Display options
Share it on

Sex Transm Infect. 2012 Nov;88(7):517-21. doi: 10.1136/sextrans-2011-050161. Epub 2012 May 29.

Quality of life valuations of HPV-associated cancer health states by the general population.

Sexually transmitted infections

E Lynne Conway, K Chip Farmer, William J Lynch, Guy L Rees, Gerard Wain, Jane Adams

Affiliations

  1. CSL Biotherapies, 45 Poplar Road, Parkville, VIC 3052, Australia. [email protected]

PMID: 22645393 PMCID: PMC3595496 DOI: 10.1136/sextrans-2011-050161

Abstract

OBJECTIVES: To obtain health-related quality of life valuations (ie, utilities) for human papillomavirus (HPV)-related cancer health states of vulval, vaginal, penile, anal and oropharyngeal cancers for use in modelling cost-effectiveness of prophylactic HPV vaccination.

METHODS: Written case descriptions of each HPV-associated cancer describing the 'average' patient surviving after the initial cancer diagnosis and treatment were developed in consultation with oncology clinicians. A general overview, standard gamble questionnaire for each health state and a quiz was conducted in 120 participants recruited from the general population.

RESULTS: In the included population sample (n=99), the average age was 43 years (range = 18-70 years) with 54% men, 44% never married/43% married, 76% education beyond year 12 and 39% employed full-time. The utility values for the five health states were 0.57 (95% CI 0.52 to 0.62) for anal cancer, 0.58 (0.53 to 0.63) for oropharyngeal cancer, 0.59 (0.54 to 0.64) for vaginal cancer, 0.65 (0.60 to 0.70) for vulval cancer and 0.79 (0.74 to 0.84) for penile cancer. Participants demonstrated a very good understanding of the symptoms, diagnosis and treatment of these cancers with a mean score of 9 (SD=1.1) on a 10-item quiz.

CONCLUSIONS: This study provides utility estimates for the specific HPV-related cancers of vulval, vaginal, penile, anal and oropharyngeal cancers valued by a general population sample using standard gamble. The results demonstrate considerable quality of life impact associated with surviving these cancers that will be important to incorporate into modelling cost-effectiveness of prophylactic HPV vaccination in different populations.

References

  1. Health Econ. 2008 May;17(5):593-605 - PubMed
  2. Cancer. 2008 Nov 15;113(10 Suppl):2892-900 - PubMed
  3. Value Health. 2009 Jul-Aug;12(5):750-8 - PubMed
  4. BMJ. 2009 Oct 08;339:b3884 - PubMed
  5. Br J Cancer. 2009 Aug 4;101(3):387-9 - PubMed
  6. J Clin Oncol. 2007 Jun 1;25(16):2191-7 - PubMed
  7. Pharmacoeconomics. 1999 Feb;15(2):119-27 - PubMed
  8. Am J Gastroenterol. 1999 Jun;94(6):1650-7 - PubMed
  9. BJOG. 2007 Apr;114(4):391-7 - PubMed
  10. Ann Surg Oncol. 2008 Jul;15(7):1948-58 - PubMed
  11. Cancer. 2008 Nov 15;113(10 Suppl):2901-9 - PubMed
  12. Eur Urol. 2008 Jul;54(1):161-8 - PubMed
  13. Clin Oncol (R Coll Radiol). 2004 Dec;16(8):530-5 - PubMed
  14. Int J Gynecol Cancer. 2004 Sep-Oct;14(5):875-81 - PubMed
  15. Oncology. 2005;68(4-6):405-13 - PubMed
  16. BMC Urol. 2009 Aug 08;9:8 - PubMed
  17. Gynecol Oncol. 2007 Jun;105(3):600-3 - PubMed
  18. Crit Rev Oncol Hematol. 2007 Jun;62(3):251-67 - PubMed
  19. Sex Health. 2010 Sep;7(3):352-8 - PubMed
  20. Cancer. 2008 Nov 15;113(10 Suppl):2873-82 - PubMed
  21. Cancer. 2008 Nov 15;113(10 Suppl):2883-91 - PubMed
  22. Adolesc Med State Art Rev. 2010 Aug;21(2):347-63, x-xi - PubMed
  23. J Clin Virol. 2005 Mar;32 Suppl 1:S16-24 - PubMed
  24. Int J Radiat Oncol Biol Phys. 2002 Nov 1;54(3):742-51 - PubMed
  25. Sex Transm Infect. 2011 Oct;87(6):458-63 - PubMed
  26. Soc Sci Med. 1991;32(9):981-7 - PubMed

MeSH terms

Publication Types